BR0212895A - Methods and compositions of novel triazine compounds - Google Patents

Methods and compositions of novel triazine compounds

Info

Publication number
BR0212895A
BR0212895A BR0212895-0A BR0212895A BR0212895A BR 0212895 A BR0212895 A BR 0212895A BR 0212895 A BR0212895 A BR 0212895A BR 0212895 A BR0212895 A BR 0212895A
Authority
BR
Brazil
Prior art keywords
compounds
present
compositions
methods
cell proliferation
Prior art date
Application number
BR0212895-0A
Other languages
Portuguese (pt)
Inventor
Richard T Timmer
Sivaram Pillarisetti
Uday Saxena
Karen A Campbell
Christopher W Alexander
Original Assignee
Reddy Us Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy Us Therapeutics Inc filed Critical Reddy Us Therapeutics Inc
Publication of BR0212895A publication Critical patent/BR0212895A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)

Abstract

"MéTODOS E COMPOSIçõES DE NOVOS COMPOSTOS DA TRIAZINA". A presente invenção se refere a métodos e composições compreendendo compostos que tratam condições fisiopatológicas surgidas a partir de respostas inflamatórias. Em particular, a presente invenção está direcionada a compostos que inibem ou bloqueiam a indução da sinalização associada com a resposta inflamatória produzida pelas proteínas glicatadas nas células do tecido endotelial. A presente invenção se refere a compostos que inibem a proliferação de células da musculatura lisa. Em particular, a presente invenção está direcionada a compostos que inibem a proliferação de células da musculatura lisa pela modulação de HSPGs tais como o Perlecan. A presente invenção também se refere ao uso de compostos para tratar as condições vasculares oclusivas caracterizadas pela proliferação das células da musculatura lisa tais como re-estenose e aterosclerose."METHODS AND COMPOSITIONS OF NEW Triazine Compounds". The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block the induction of signaling associated with the inflammatory response produced by glycated proteins in endothelial tissue cells. The present invention relates to compounds that inhibit smooth muscle cell proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention also relates to the use of compounds to treat occlusive vascular conditions characterized by smooth muscle cell proliferation such as restenosis and atherosclerosis.

BR0212895-0A 2001-09-21 2002-09-23 Methods and compositions of novel triazine compounds BR0212895A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32414701P 2001-09-21 2001-09-21
PCT/US2002/030177 WO2003024926A2 (en) 2001-09-21 2002-09-23 Methods and compositions of novel triazine compounds

Publications (1)

Publication Number Publication Date
BR0212895A true BR0212895A (en) 2005-05-10

Family

ID=23262298

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212895-0A BR0212895A (en) 2001-09-21 2002-09-23 Methods and compositions of novel triazine compounds

Country Status (16)

Country Link
EP (1) EP1436266A4 (en)
JP (1) JP2005511509A (en)
KR (1) KR20040088457A (en)
CN (1) CN1578773A (en)
BR (1) BR0212895A (en)
CA (1) CA2461074A1 (en)
EA (1) EA009728B1 (en)
IL (1) IL160984A0 (en)
IS (1) IS7190A (en)
MX (1) MXPA04002680A (en)
NO (1) NO20041187L (en)
NZ (1) NZ532349A (en)
PL (1) PL369600A1 (en)
RS (1) RS34004A (en)
WO (1) WO2003024926A2 (en)
ZA (1) ZA200403009B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
CN1625410A (en) 2002-02-05 2005-06-08 山之内制药株式会社 2,4,6-triamino-1,3,5-triazine derivative
AU2003253735A1 (en) * 2002-06-25 2004-01-06 The Center For Blood Research, Inc. Vacuolins
WO2005009980A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
CN1629157A (en) * 2003-12-19 2005-06-22 中国科学院上海药物研究所 Piperazinyl triazine compounds, preparation method thereof and pharmaceutical composition containing same
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
ES2350803T3 (en) * 2006-11-03 2011-01-27 Nerviano Medical Sciences S.R.L. PROCEDURE FOR ADMINISTRATION OF AN ANTITUMORAL COMPOUND.
KR101314869B1 (en) * 2010-07-29 2013-10-04 광주과학기술원 Pharmaceutical Compositions for Treating or Preventing Diabetes Comprising Triazine Compound as an Active Ingredient
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
JP5907986B2 (en) * 2010-11-29 2016-04-26 ガリオン ファーマシューティカルズ インコーポレイテッド Compounds as respiratory stimulants for the treatment of respiratory control disorders or respiratory control disorders
US10604492B2 (en) * 2015-12-24 2020-03-31 The Regents Of The Universtiy Of California CFTR regulators and methods of use thereof
KR20200044873A (en) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Eye pharmaceutical composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083568C1 (en) * 1994-05-05 1997-07-10 Кубанский государственный аграрный университет Triazinecarboxylic acid salts and agent for presowing treatment of agriculture crop seeds
DE19531084A1 (en) * 1995-08-24 1997-02-27 Hoechst Schering Agrevo Gmbh 2,4-diamino-1,3,5-triazines, process for their preparation and their use as herbicides and plant growth regulators
ATE239012T1 (en) * 1997-12-12 2003-05-15 Abbott Lab TRIAZINE ANGIOGENESIS INHIBITORS
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
JP4794793B2 (en) * 1999-12-28 2011-10-19 ファーマコペイア， インコーポレイテッド N-heterocyclic TNF-α expression inhibitor
AU2002216650A1 (en) * 2000-10-31 2002-05-15 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof

Also Published As

Publication number Publication date
KR20040088457A (en) 2004-10-16
JP2005511509A (en) 2005-04-28
EA200400464A1 (en) 2005-02-24
CA2461074A1 (en) 2003-03-27
CN1578773A (en) 2005-02-09
IL160984A0 (en) 2004-08-31
MXPA04002680A (en) 2004-06-18
ZA200403009B (en) 2007-12-27
NZ532349A (en) 2007-02-23
IS7190A (en) 2004-03-19
EP1436266A4 (en) 2004-12-22
EP1436266A2 (en) 2004-07-14
WO2003024926A2 (en) 2003-03-27
WO2003024926A3 (en) 2003-12-11
EA009728B1 (en) 2008-02-28
RS34004A (en) 2006-10-27
NO20041187L (en) 2004-05-19
PL369600A1 (en) 2005-05-02

Similar Documents

Publication Publication Date Title
BR0314670A (en) Methods and compositions of triazine compounds
BR0212895A (en) Methods and compositions of novel triazine compounds
DK0696297T3 (en) Pyridobisimidazole-based rigid rod polymer
TR199800353T1 (en) Post-operative anti-adhesion biomaterials.
DE69936351D1 (en) GLYCOSYLATED PROTEINS WITH REDUCED ALLERGENITY
BR0110587A (en) Ion-sensitive heavy water dispersible polymers
PT1140944E (en) EPOTILONE DERIVATIVES AND THEIR USE AS ANTITUMATIC AGENTS
BR9812764A (en) Dough compositions made with dehydrated potato flakes
DE69516847D1 (en) CHLORPYRIMIDINE AS INTERMEDIATE PRODUCTS
DE69622413D1 (en) COMPOSIBLE PLAYING DEVICE, IN PARTICULAR FOR THE PRODUCTION OF ROLLERWAYS
DE69534961D1 (en) MAGNIFICATION OF THE MOLECULAR WEIGHT OF POLYCONDENSATES
DE60225590D1 (en) C-KITHEMMER FOR THE TREATMENT OF BACTERIAL INFECTIONS
DE69913543T8 (en) Dermal scaffold based on a neutralized chitosan sponge or a neutralized mixed chitosan-collagen sponge
DK0869970T3 (en) Endothelial cell proliferation inhibitor and its use
ES2190535T3 (en) LECTIN COMPOSITIONS AND USE OF THE SAME.
ATE240052T1 (en) IRON ENRICHMENT SYSTEM
ATE272071T1 (en) USE OF A HIGHER MOLECULAR WEIGHT EXTRACELLULAR HEMOGLOBIN AS A BLOOD SUBSTITUTE
IT8423691A0 (en) APPLIANCE FOR THE TREATMENT OF MEAT OR HAM, IN PARTICULAR SALMED PRODUCTS TO BE COOKED.
PT1092040E (en) METHODS OF INHIBIT HELICOBACTER PYLORI
TR200001927T2 (en) Carboxyl substituted chromone derivatives useful as beta 3 adrenoreceptor agonists.
ES2095192A1 (en) Burn ointment
ATE442149T1 (en) USE OF ORGANIC GLUCOSAMINE SALTS
WO2001002031A3 (en) Targeted anticalcification treatment
BR0016616A (en) Attenuated microorganisms for the treatment of infection
ES2196802T3 (en) CITRONELYL AND / OR DIHYDROCITRONELILE LACTATES, THEIR PREPARATION AND THEIR USE.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.